Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

ESSPRI and other patient-reported indices in patients with primary Sjogren's syndrome during 100 consecutive outpatient visits at one rheumatological clinic.

Pertovaara M, Korpela M.

Rheumatology (Oxford). 2014 May;53(5):927-31. doi: 10.1093/rheumatology/ket476. Epub 2014 Jan 24.

PMID:
24464708
2.

European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index: a complete picture of primary Sjögren's syndrome patients.

Seror R, Gottenberg JE, Devauchelle-Pensec V, Dubost JJ, Le Guern V, Hayem G, Fauchais AL, Goeb V, Hachulla E, Hatron PY, Larroche C, Morel J, Pedriger A, Puechal X, Rist S, Saraux A, Sene D, Sibilia J, Vittecoq O, Zarnitsky C, Labetoulle M, Ravaud P, Mariette X.

Arthritis Care Res (Hoboken). 2013 Aug;65(8):1358-64. doi: 10.1002/acr.21991.

3.

Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.

Meiners PM, Arends S, Brouwer E, Spijkervet FK, Vissink A, Bootsma H.

Ann Rheum Dis. 2012 Aug;71(8):1297-302. doi: 10.1136/annrheumdis-2011-200460. Epub 2012 Jan 17.

PMID:
22258489
4.

Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI).

Seror R, Theander E, Brun JG, Ramos-Casals M, Valim V, Dörner T, Bootsma H, Tzioufas A, Solans-Laqué R, Mandl T, Gottenberg JE, Hachulla E, Sivils KL, Ng WF, Fauchais AL, Bombardieri S, Valesini G, Bartoloni E, Saraux A, Tomsic M, Sumida T, Nishiyama S, Caporali R, Kruize AA, Vollenweider C, Ravaud P, Vitali C, Mariette X, Bowman SJ; EULAR Sjögren's Task Force.

Ann Rheum Dis. 2015 May;74(5):859-66. doi: 10.1136/annrheumdis-2013-204615. Epub 2014 Jan 17.

PMID:
24442883
5.

Do the EULAR Sjögren's syndrome outcome measures correlate with health status in primary Sjögren's syndrome?

Lendrem D, Mitchell S, McMeekin P, Gompels L, Hackett K, Bowman S, Price E, Pease CT, Emery P, Andrews J, Lanyon P, Hunter J, Gupta M, Bombardieri M, Sutcliffe N, Pitzalis C, McLaren J, Cooper A, Regan M, Giles I, Isenberg D, Saravanan V, Coady D, Dasgupta B, McHugh N, Young-Min S, Moots R, Gendi N, Akil M, Griffiths B, Ng WF; UK primary Sjögren’s Syndrome Registry.

Rheumatology (Oxford). 2015 Apr;54(4):655-9. doi: 10.1093/rheumatology/keu361. Epub 2014 Sep 19.

PMID:
25240612
6.

The EULAR Sjogren's syndrome patient reported index as an independent determinant of health-related quality of life in primary Sjogren's syndrome patients: in comparison with non-Sjogren's sicca patients.

Cho HJ, Yoo JJ, Yun CY, Kang EH, Lee HJ, Hyon JY, Song YW, Lee YJ.

Rheumatology (Oxford). 2013 Dec;52(12):2208-17. doi: 10.1093/rheumatology/ket270. Epub 2013 Sep 10.

PMID:
24023247
7.

Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI).

Seror R, Bootsma H, Saraux A, Bowman SJ, Theander E, Brun JG, Baron G, Le Guern V, Devauchelle-Pensec V, Ramos-Casals M, Valim V, Dörner T, Tzioufas A, Gottenberg JE, Solans Laqué R, Mandl T, Hachulla E, Sivils KL, Ng WF, Fauchais AL, Bombardieri S, Priori R, Bartoloni E, Goeb V, Praprotnik S, Sumida T, Nishiyama S, Caporali R, Kruize AA, Vollenweider C, Ravaud P, Meiners P, Brito-Zerón P, Vitali C, Mariette X; EULAR Sjögren's Task Force.

Ann Rheum Dis. 2016 Feb;75(2):382-9. doi: 10.1136/annrheumdis-2014-206008. Epub 2014 Dec 5.

PMID:
25480887
8.

The impact of primary Sjögren's syndrome on female sexual function.

van Nimwegen JF, Arends S, van Zuiden GS, Vissink A, Kroese FG, Bootsma H.

Rheumatology (Oxford). 2015 Jul;54(7):1286-93. doi: 10.1093/rheumatology/keu522. Epub 2015 Feb 4.

PMID:
25652072
9.

Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren's syndrome. Data at enrollment in the prospective ASSESS cohort.

Gottenberg JE, Seror R, Miceli-Richard C, Benessiano J, Devauchelle-Pensec V, Dieude P, Dubost JJ, Fauchais AL, Goeb V, Hachulla E, Hatron PY, Larroche C, Le Guern V, Morel J, Perdriger A, Puéchal X, Rist S, Saraux A, Sene D, Sibilia J, Vittecoq O, Nocturne G, Ravaud P, Mariette X.

PLoS One. 2013 May 24;8(5):e59868. doi: 10.1371/journal.pone.0059868. Print 2013.

10.

Outcome measures for primary Sjögren's syndrome: a comprehensive review.

Seror R, Theander E, Bootsma H, Bowman SJ, Tzioufas A, Gottenberg JE, Ramos-Casals M, Dörner T, Ravaud P, Mariette X, Vitali C.

J Autoimmun. 2014 Jun;51:51-6. doi: 10.1016/j.jaut.2013.12.010. Epub 2014 Jan 8. Review.

PMID:
24411404
11.

Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.

Cornec D, Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puéchal X, Le Guern V, Sibilia J, Gottenberg JE, Chiche L, Hachulla E, Yves Hatron P, Goeb V, Hayem G, Morel J, Zarnitsky C, Dubost JJ, Saliou P, Pers JO, Seror R, Saraux A.

Arthritis Care Res (Hoboken). 2017 Apr;69(4):528-535. doi: 10.1002/acr.22974.

12.

EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome.

Seror R, Ravaud P, Mariette X, Bootsma H, Theander E, Hansen A, Ramos-Casals M, Dörner T, Bombardieri S, Hachulla E, Brun JG, Kruize AA, Praprotnik S, Tomsic M, Gottenberg JE, Devauchelle V, Devita S, Vollenweider C, Mandl T, Tzioufas A, Carsons S, Saraux A, Sutcliffe N, Vitali C, Bowman SJ; EULAR Sjögren's Task Force.

Ann Rheum Dis. 2011 Jun;70(6):968-72. doi: 10.1136/ard.2010.143743. Epub 2011 Feb 22.

PMID:
21345815
14.

Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).

Meiners PM, Vissink A, Kroese FG, Spijkervet FK, Smitt-Kamminga NS, Abdulahad WH, Bulthuis-Kuiper J, Brouwer E, Arends S, Bootsma H.

Ann Rheum Dis. 2014 Jul;73(7):1393-6. doi: 10.1136/annrheumdis-2013-204653. Epub 2014 Jan 28.

PMID:
24473674
15.

Prevalence and clinical impact of fibromyalgia in patients with primary Sjögren's syndrome.

Choi BY, Oh HJ, Lee YJ, Song YW.

Clin Exp Rheumatol. 2016 Mar-Apr;34(2 Suppl 96):S9-13. Epub 2015 Aug 27.

PMID:
26315451
16.

Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren's syndrome.

Gottenberg JE, Busson M, Cohen-Solal J, Lavie F, Abbed K, Kimberly RP, Sibilia J, Mariette X.

Ann Rheum Dis. 2005 Jul;64(7):1050-5. Epub 2005 Jan 7.

17.

EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome.

Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, Gottenberg JE, Bootsma H, Mariette X, Vitali C; EULAR Sjögren's Task Force.

Ann Rheum Dis. 2010 Jun;69(6):1103-9. doi: 10.1136/ard.2009.110619. Epub 2009 Jun 28. Erratum in: Ann Rheum Dis. 2011 May;70(5):880.

18.

Transcultural adaptation of the "EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI)" into Brazilian Portuguese.

Serrano EV, Valim V, Miyamoto ST, Giovelli RA, Paganotti MA, Cadê NV.

Rev Bras Reumatol. 2013 Nov-Dec;53(6):483-93. doi: 10.1016/j.rbr.2013.04.003. English, Portuguese.

19.

Serum β2 microglobulin correlates with the new ESSDAI in patients with Sjögren's syndrome.

Pertovaara M, Korpela M.

Ann Rheum Dis. 2011 Dec;70(12):2236-7. doi: 10.1136/ard.2011.153098. Epub 2011 May 30. No abstract available.

PMID:
21628309
20.

Serum 25-Hydroxyvitamin D3 and BAFF Levels Are Associated with Disease Activity in Primary Sjogren's Syndrome.

Lee SJ, Oh HJ, Choi BY, Jang YJ, Lee JY, Park JK, Song YW.

J Immunol Res. 2016;2016:5781070. doi: 10.1155/2016/5781070. Epub 2016 Dec 15.

Supplemental Content

Support Center